Why the study?
Do clinical factors and gene polymorphisms of CYP2C19 and CYP4F2 increase the risk of early coronary stent thrombosis?
Do clinical factors and gene polymorphisms of CYP2C19 and CYP4F2 increase the risk of early coronary stent thrombosis?
The CYP4F2 G1347A polymorphism and CYP2C19*2*2 genotype are independently associated with an increased risk of early coronary stent thrombosis.
CYP genotyping may flag early stent thrombosis risk; hypothesis-generating pending prospective validation.
AIM: To determine the main clinical and genetic factors having impact on early coronary stent thrombosis. MATERIALS & METHODS: Genotyping of CYP2C19*2, *17 and CYP4F2*3 in patients with (n = 31) and without stent thrombosis (n = 456) was performed. Clinical and genetic data were analyzed by binary logistic regression. RESULTS: Smoking (OR: 0.317; 95% CI: 0.131-0.767), high-density lipoprotein level in mmol/l (OR: 0.142; 95% CI: 0.040-0.506), CYP2C19*2*2 versus *1*1 and *1*2 genotype (OR: 11.625; 95% CI: 3.498-38.633), CYP4F2 AA versus GA and GG genotype (OR: 3.532; 95% CI: 1.153-10.822) were associated with early stent thrombosis. CONCLUSION: For the first time we have identified a clinically important polymorphism (CYP4F2 G1347A) that was independently associated with early stent thrombosis. Original submitted 18 August 2014; Revision submitted 10 November 2014.
No takes yet. Share an insight, caveat, or question.
Kupstytė et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: